The stock of TherapeuticsMD Inc (NYSEMKT:TXMD) is a huge mover today! About 2.85M shares traded hands or 0.35% up from the average. TherapeuticsMD Inc (NYSEMKT:TXMD) has declined 31.59% since April 27, 2016 and is downtrending. It has underperformed by 36.81% the S&P500.
The move comes after 6 months positive chart setup for the $987.12M company. It was reported on Nov, 30 by Barchart.com. We have $6.42 PT which if reached, will make NYSEMKT:TXMD worth $78.97M more.
Analysts await TherapeuticsMD Inc (NYSEMKT:TXMD) to report earnings on February, 23. They expect $-0.13 EPS, down 30.00% or $0.03 from last year’s $-0.1 per share. After $-0.13 actual EPS reported by TherapeuticsMD Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.
TherapeuticsMD Inc (NYSEMKT:TXMD) Ratings Coverage
Out of 4 analysts covering TherapeuticsMD (NYSEMKT:TXMD), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. TherapeuticsMD has been the topic of 6 analyst reports since September 21, 2015 according to StockzIntelligence Inc. On Tuesday, November 22 the stock rating was reinitiated by Jefferies with “Buy”. Jefferies maintained TherapeuticsMD Inc (NYSEMKT:TXMD) rating on Tuesday, December 8. Jefferies has “Buy” rating and $18.0 price target. The stock of TherapeuticsMD Inc (NYSEMKT:TXMD) has “Buy” rating given on Monday, September 21 by Jefferies. The company was initiated on Tuesday, November 22 by Oppenheimer. The firm has “Buy” rating given on Tuesday, December 8 by Stifel Nicolaus.
According to Zacks Investment Research, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida.”
Insitutional Activity: The institutional sentiment increased to 1.32 in Q2 2016. Its up 0.07, from 1.25 in 2016Q1. The ratio improved, as 19 funds sold all TherapeuticsMD Inc shares owned while 29 reduced positions. 13 funds bought stakes while 47 increased positions. They now own 158.58 million shares or 4.25% more from 152.12 million shares in 2016Q1.
Barometer Cap Management has invested 0.05% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD). Ladenburg Thalmann Fincl Services holds 0% or 16,325 shares in its portfolio. Commonwealth Equity Ser Incorporated holds 0% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD) for 17,100 shares. Schwab Charles Inv Inc holds 0.01% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD) for 511,630 shares. Geode Capital Lc has 1.01M shares for 0% of their US portfolio. The Maryland-based Rock Springs Cap Mngmt Lp has invested 0.99% in TherapeuticsMD Inc (NYSEMKT:TXMD). First Midwest State Bank Trust Division reported 27,800 shares or 0.03% of all its holdings. The Switzerland-based Gam Holdings Ag has invested 0.1% in TherapeuticsMD Inc (NYSEMKT:TXMD). Virginia Retirement Systems Et Al accumulated 60,900 shares or 0.01% of the stock. Kcg holds 0% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD) for 13,571 shares. Alpine Woods Capital Invsts Limited Liability Co last reported 12,000 shares in the company. Credit Suisse Ag last reported 117,293 shares in the company. Proshare Advisors Ltd Liability Com has 0% invested in the company for 18,356 shares. Millennium Ltd Company has 372,275 shares for 0.01% of their US portfolio. Blackrock holds 0% or 15,223 shares in its portfolio.
Another recent and important TherapeuticsMD Inc (NYSEMKT:TXMD) news was published by Fool.com which published an article titled: “Is This Why Shares of TherapeuticsMD Inc. Rose Today?” on November 04, 2016.
TXMD Company Profile
TherapeuticsMD, Inc., incorporated on July 20, 2010, is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. The Firm is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The Company’s drug candidates used in its clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. The Company’s drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination. The Firm makes and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.